Discovery of Genetic Basis of Mendelian or Monogenic Heart, Lung, and Blood Disorders (X01) | Apply Online

Frequently Asked Questions (FAQs)

What is the "Discovery of Genetic Basis of Mendelian or Monogenic Heart, Lung, and Blood Disorders (X01)" opportunity?

This is an NHLBI (National Heart, Lung, and Blood Institute) program intended to help researchers identify the specific genetic causes of single-gene (Mendelian or monogenic) disorders that strongly affect the heart, lungs, or blood systems. The emphasis is on gene discovery and pinpointing disease-causing variants in well-defined inherited HLB conditions.

What does the X01 funding mechanism mean for applicants?

The X01 mechanism is commonly used when NIH is providing access to a resource or service rather than issuing a traditional research grant budget. In this opportunity, the central offering is access to exome sequencing via an established national sequencing resource, not primarily funding to purchase sequencing independently.

What is the main resource provided through this opportunity?

The central feature is access to exome sequencing through the Mendelian Disorders Genome Centers (MDGCs). Applicants apply for the chance to use this sequencing capacity to generate high-quality exome data to accelerate gene and variant discovery.

Is the primary purpose to pay for sequencing costs?

No. The opportunity is described as providing access to exome sequencing through the MDGCs, rather than primarily funding applicants to buy sequencing on their own.

What kinds of diseases are within scope?

The scientific scope is tightly centered on Mendelian or monogenic disorders with meaningful relevance to heart, lung, or blood biology. The strongest fit is typically inherited, high-penetrance disease where exome sequencing is likely to be informative.

What types of study characteristics are emphasized as strong for this program?

Projects tend to be strongest when they involve clear evidence of inherited, high-penetrance disease, strong phenotyping, and carefully selected families or cases where exome sequencing is likely to yield informative results about causal genes or variants.

Which NIH institute administers this opportunity?

The opportunity is administered through the National Institutes of Health (NIH), specifically the National Heart, Lung, and Blood Institute (NHLBI).

Is this opportunity still open to new applications?

No. The announcement listed an original and final application closing date of May 14, 2014, with an archive date of June 14, 2014. That indicates the opportunity is no longer open for new applications under that specific announcement.

When was the announcement posted?

The funding announcement was posted and created on August 12, 2011.

What was the final application due date?

The final (and original) application closing date listed for this announcement was May 14, 2014.

What does the archive date mean?

The archive date (June 14, 2014) indicates the announcement was moved into an archived status and is no longer active for new submissions under that specific opportunity posting.

Was cost sharing or matching required?

No. The program did not require cost sharing or matching funds.

Who was eligible to apply?

Eligibility was broad and included many U.S. governmental entities (state, county, city or township, special district governments), public and private institutions of higher education, independent school districts, public housing authorities/Indian housing authorities, nonprofit organizations (with or without 501(c)(3) status), and for-profit organizations (including small businesses and other for-profit entities).

Were tribal entities and institutions serving specific populations eligible?

Yes. The eligibility rules were inclusive of tribal entities and institutions serving specific populations, including Historically Black Colleges and Universities (HBCUs), Hispanic-serving institutions, Alaska Native and Native Hawaiian Serving Institutions, and Tribally Controlled Colleges and Universities (TCCUs).

Could foreign organizations apply?

Yes. Non-U.S. entities were allowed to apply. Foreign institutions were eligible, non-domestic components of U.S. organizations could participate, and foreign components (as defined by NIH policy) were permitted.

Were faith-based and community-based organizations eligible?

Yes. Faith-based and community-based organizations were included among eligible applicants, along with regional organizations and eligible federal agencies, as long as the proposed study fit the scientific scope.

What CFDA numbers were associated with this opportunity?

The opportunity was associated with multiple CFDA numbers tied to NHLBI research areas: 93.233 (National Center on Sleep Disorders Research), 93.837 (Cardiovascular Diseases Research), 93.838 (Lung Diseases Research), and 93.839 (Blood Diseases and Resources Research).

What do the multiple CFDA numbers imply about the program's scientific breadth?

The spread across cardiovascular, lung, blood, and sleep-related CFDA areas underscores that a range of HLB conditions could fit, as long as the disorder is consistent with Mendelian or monogenic inheritance and is meaningfully relevant to heart, lung, or blood health.

Where were official details provided at the time?

The full announcement was hosted on the NIH grants site (linked in the notice), which served as the official source for the details during the active period of the opportunity.

Who was the contact for technical issues with the posting?

For technical issues accessing or linking to the announcement, the listed contact was the NIH Office of Extramural Research (OER) webmaster at FBOWebmaster@OD.NIH.GOV.

Is the listed contact intended for scientific questions about project fit?

The provided contact information is described as typical for legacy postings where questions relate to the electronic announcement itself rather than scientific program content. The information provided identifies a technical contact for access/linking issues.